Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1001904#aggregation> ?p ?o. }
Showing items 1 to 43 of
43
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B605229.
- aggregation creator B605230.
- aggregation creator B605231.
- aggregation creator B605232.
- aggregation creator B605233.
- aggregation creator B605234.
- aggregation creator B605235.
- aggregation creator B605236.
- aggregation creator B605237.
- aggregation creator B605238.
- aggregation creator B605239.
- aggregation creator B605240.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1001904.bibtex.
- aggregation hasFormat 1001904.csv.
- aggregation hasFormat 1001904.dc.
- aggregation hasFormat 1001904.didl.
- aggregation hasFormat 1001904.doc.
- aggregation hasFormat 1001904.json.
- aggregation hasFormat 1001904.mets.
- aggregation hasFormat 1001904.mods.
- aggregation hasFormat 1001904.rdf.
- aggregation hasFormat 1001904.ris.
- aggregation hasFormat 1001904.txt.
- aggregation hasFormat 1001904.xls.
- aggregation hasFormat 1001904.yaml.
- aggregation isPartOf urn:issn:0001-5644.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients".
- aggregation abstract "Background/Aims : A large multicenter trial to compare the efficacy of peginterferon alfa-2a with interferon alfa-2a, in combination with ribavirin, in chronic hepatitis C patients. Efficacy data for prior relapsers are reported because treatment recommendations for this patient population are not well defined. Patients and methods : This study was a multicenter, prospective, randomized clinical trial. The primary efficacy endpoint was sustained virologic response in naive patients (n = 348) and relapsers (n = 95). Results : Sustained virologic response rates were similar in naive patients and relapsers, both for non-pegylated and pegylated interferon (respectively 27 and 26% and 54 and 43%). Pegylated interferon given for 48 weeks did not improved the relapse rate : 15.9 and 27.3% for non-pegylated and 16.7 and 30.4% for pegylated interferon, naive vs relapsers respectively. Stepwise logistic regression analysis revealed a significant association between slow response (detectable HCV RNA at week 12 and undetectable at week 24) and relapse in patients with an end-of-treatment response (55% versus 13% respectively; p = 0.02; odds ratio = 6.07). Conclusions : This trial confirms the value of using peginterferon alfa-2a in both naive and relapsed patients and provides support for a more tailored approach to treatment for relapsers and particulary for patients with a slow viral response.".
- aggregation authorList BK960948.
- aggregation endPage "228".
- aggregation issue "2".
- aggregation startPage "223".
- aggregation volume "73".
- aggregation aggregates 1001905.
- aggregation isDescribedBy 1001904.
- aggregation similarTo LU-1001904.